MX2019007797A - Antagonistas de integrinas. - Google Patents
Antagonistas de integrinas.Info
- Publication number
- MX2019007797A MX2019007797A MX2019007797A MX2019007797A MX2019007797A MX 2019007797 A MX2019007797 A MX 2019007797A MX 2019007797 A MX2019007797 A MX 2019007797A MX 2019007797 A MX2019007797 A MX 2019007797A MX 2019007797 A MX2019007797 A MX 2019007797A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical agents
- integrins
- compounds
- integrin antagonists
- avß8
- Prior art date
Links
- 102000006495 integrins Human genes 0.000 title abstract 3
- 108010044426 integrins Proteins 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662440253P | 2016-12-29 | 2016-12-29 | |
| US201762471882P | 2017-03-15 | 2017-03-15 | |
| PCT/US2017/068801 WO2018132268A1 (en) | 2016-12-29 | 2017-12-28 | Integrin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019007797A true MX2019007797A (es) | 2019-10-21 |
Family
ID=62840040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007797A MX2019007797A (es) | 2016-12-29 | 2017-12-28 | Antagonistas de integrinas. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11306084B2 (enExample) |
| EP (1) | EP3562826A4 (enExample) |
| JP (1) | JP2020504120A (enExample) |
| KR (1) | KR20190100232A (enExample) |
| CN (1) | CN110177787A (enExample) |
| AU (1) | AU2017393297A1 (enExample) |
| BR (1) | BR112019012515A2 (enExample) |
| CA (1) | CA3045491A1 (enExample) |
| CO (1) | CO2019007023A2 (enExample) |
| IL (1) | IL267686A (enExample) |
| MX (1) | MX2019007797A (enExample) |
| PH (1) | PH12019501514A1 (enExample) |
| RU (1) | RU2019116820A (enExample) |
| WO (1) | WO2018132268A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3045491A1 (en) | 2016-12-29 | 2018-07-19 | Indalo Therapeutics, Inc. | Integrin antagonists |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| EP4159727B1 (en) | 2017-02-28 | 2026-04-08 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| PT3844162T (pt) | 2018-08-29 | 2025-03-28 | Morphic Therapeutic Inc | Inibidores da integrina alfa v beta6 |
| AU2019327475B2 (en) | 2018-08-29 | 2025-06-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| WO2024145245A2 (en) * | 2022-12-27 | 2024-07-04 | Pliant Therapeutics, Inc. | Alpha-v-beta-8 integrin inhibitors and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004511434A (ja) * | 2000-06-15 | 2004-04-15 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸 |
| MXPA05006588A (es) * | 2002-12-20 | 2005-08-16 | Pharmacia Corp | Compuestos de pirazol como derivados antagonistas del receptor de la integrina. |
| BR0316876A (pt) | 2002-12-20 | 2005-10-25 | Pharmacia Corp | Compostos de tiazol e composição farmacêutica compreendendo o mesmo |
| BR0317600A (pt) | 2002-12-20 | 2005-11-29 | Pharmacia Corp | ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina |
| IN2015DN00099A (enExample) * | 2012-07-18 | 2015-05-29 | Univ Saint Louis | |
| US8716226B2 (en) * | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
| AU2014324426A1 (en) | 2013-09-30 | 2016-04-21 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| AU2017359028A1 (en) | 2016-11-08 | 2019-06-20 | Bristol-Myers Squibb Company | Azole amides and amines as alpha V integrin inhibitors |
| CN110167934B (zh) | 2016-11-08 | 2022-06-10 | 百时美施贵宝公司 | 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物 |
| EA201991123A1 (ru) | 2016-11-08 | 2019-11-29 | ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV | |
| EP3538528B1 (en) | 2016-11-08 | 2020-12-23 | Bristol-Myers Squibb Company | Pyrrole amides as alpha v integrin inhibitors |
| PT3538525T (pt) | 2016-11-08 | 2022-08-16 | Bristol Myers Squibb Co | Ácidos propiónicos 3-substituídos por inibidores de alfa v integrina |
| CA3045491A1 (en) | 2016-12-29 | 2018-07-19 | Indalo Therapeutics, Inc. | Integrin antagonists |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| US20210284638A1 (en) | 2018-07-03 | 2021-09-16 | Saint Louis University | ALPHAvBETA1 INTEGRIN ANTAGONISTS |
-
2017
- 2017-12-28 CA CA3045491A patent/CA3045491A1/en not_active Abandoned
- 2017-12-28 US US16/474,505 patent/US11306084B2/en active Active
- 2017-12-28 MX MX2019007797A patent/MX2019007797A/es unknown
- 2017-12-28 KR KR1020197019720A patent/KR20190100232A/ko not_active Withdrawn
- 2017-12-28 EP EP17891632.6A patent/EP3562826A4/en not_active Withdrawn
- 2017-12-28 BR BR112019012515-9A patent/BR112019012515A2/pt not_active Application Discontinuation
- 2017-12-28 WO PCT/US2017/068801 patent/WO2018132268A1/en not_active Ceased
- 2017-12-28 CN CN201780080614.7A patent/CN110177787A/zh active Pending
- 2017-12-28 JP JP2019534956A patent/JP2020504120A/ja active Pending
- 2017-12-28 AU AU2017393297A patent/AU2017393297A1/en not_active Abandoned
- 2017-12-28 RU RU2019116820A patent/RU2019116820A/ru not_active Application Discontinuation
-
2019
- 2019-06-26 IL IL267686A patent/IL267686A/en unknown
- 2019-06-27 PH PH12019501514A patent/PH12019501514A1/en unknown
- 2019-06-28 CO CONC2019/0007023A patent/CO2019007023A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019116820A (ru) | 2021-01-29 |
| WO2018132268A8 (en) | 2019-06-20 |
| CN110177787A (zh) | 2019-08-27 |
| AU2017393297A1 (en) | 2019-06-13 |
| JP2020504120A (ja) | 2020-02-06 |
| US11306084B2 (en) | 2022-04-19 |
| IL267686A (en) | 2019-08-29 |
| BR112019012515A2 (pt) | 2019-11-19 |
| WO2018132268A1 (en) | 2018-07-19 |
| EP3562826A4 (en) | 2020-08-26 |
| CO2019007023A2 (es) | 2019-07-31 |
| US20190345155A1 (en) | 2019-11-14 |
| PH12019501514A1 (en) | 2020-09-14 |
| EP3562826A1 (en) | 2019-11-06 |
| KR20190100232A (ko) | 2019-08-28 |
| CA3045491A1 (en) | 2018-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501514A1 (en) | Integrin antagonists | |
| ZA202500997B (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| PH12017502107A1 (en) | Triazole agonists of the apj receptor | |
| MX376465B (es) | Compuestos de pirazolo[1,5-4]piridina sustituidos como inhibidores de la quinasa ret. | |
| MX384087B (es) | Piperidinas como inhibidores de menina. | |
| WO2016023014A3 (en) | Uses of salt-inducible kinase (sik) inhibitors | |
| SG10201908839QA (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| MY192059A (en) | Heterocyclic amides as kinase inhibitors | |
| MX2017012613A (es) | Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm. | |
| MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| PH12018501362A1 (en) | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | |
| EA033497B1 (ru) | 1-(тиофенил или фенил)сульфонил-(пирролидин)-2-карбоксамидные производные и их применение в качестве антагонистов trpa1 | |
| MD20170070A2 (ro) | Derivaţi de chinazolină utilizaţi în tratamentul HIV | |
| MY193765A (en) | Sulfonylureas and related compounds and use of same | |
| MX2018003554A (es) | Benzamidas sustituidas con isoxazolina y analogos como insecticidas. | |
| WO2016011390A8 (en) | Irak4 inhibiting agents | |
| MX2019008435A (es) | Inhibidores selectivos de jak1. | |
| MX2018015247A (es) | Heterociclos de biarilmetilo. | |
| GEAP201814273A (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| PH12019500394A1 (en) | Bicyclic nitrogenated heterocyclic compound | |
| MX2018015872A (es) | Derivados de benzodioxano y su uso farmaceutico. | |
| MX2021001786A (es) | Antagonistas de integrina. | |
| SA518392179B1 (ar) | مركبات من مضاد لمستقبل سوماتوستاتين وطرق استخدامها | |
| PH12017501214A1 (en) | Cgrp antagonist peptides | |
| PH12017501334B1 (en) | 3,5-diaminopyrazole kinase inhibitors |